Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | NPY2R | P49146 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | CNR2 | P34972 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6900706 | 1.00 | DHODH (0.32) | DHODHALDH1A1NPY2RMAPTCYP3A4 | |
| SCHEMBL8169563 | 0.82 | ALDH1A1 (0.44) | ALDH1A1CYP2C19LMNACNR2POLB | |
| SCHEMBL8169561 | 0.82 | ALDH1A1 (0.44) | ALDH1A1CYP2C19LMNACNR2POLB | |
| SCHEMBL8169565 | 0.82 | ALDH1A1 (0.44) | ALDH1A1CYP2C19LMNACNR2POLB | |
| SCHEMBL27898429 | 0.80 | MEN1 (0.37) | DHODHALDH1A1 | |
| SCHEMBL21329582 | 0.75 | MEN1 (0.39) | DHODHALDH1A1LMNA | |
| SCHEMBL21329586 | 0.75 | MEN1 (0.39) | DHODHALDH1A1LMNA | |
| SCHEMBL21330105 | 0.75 | MEN1 (0.39) | DHODHALDH1A1LMNA | |
| SCHEMBL14953034 | 0.74 | DHODH (0.35) | DHODHALDH1A1NPSR1 | |
| SCHEMBL14953032 | 0.74 | DHODH (0.35) | DHODHALDH1A1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6680311-B1 | ANTICARCINOGENIC, ANTITUMOR AND ANTIPROLIFERATIVE AGENTS | ELI LILLY AND COMPANY | 2004-01-20 | — | — | US | disclosed |
| US-20020128185-A1 | Pharmaceutical compounds | HAWAII, UNIVERSITY OF | 2002-09-12 | — | — | US | disclosed |
| US-6133457-A | CRYPTOPHYCIN COMPOUNDS HAVING ANTIMICROTUBULE ACTIVITY; ANTIMETABOLITES | ELI LILLY AND COMPANY (US) | 2000-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020128185-A1 | Pharmaceutical compounds | XPO5, XPOT, XPO1 | DHODH 1310/4885ALDH1A1 4250/4885NPY2R 3769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.